HDAC6 and myeloproliferative disorder: Indeed, recent data have shown that in leukemic cells carrying the JAK2V617F mutation and in murine models of myeloproliferative neoplasms induced by the MPLW515L mutation, HDAC11 more than HDAC6 was required for cell proliferation and survival via the control of the JAK-STAT pathway [129].